Clinical Trials

Inclusion Criteria:

For subjects with LBCL:

- Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at
last relapse per WHO 2017

- At least 1 measurable lesion at time of enrollment

- Relapsed or refractory disease after at least 2 lines of chemotherapy

- Absence of significant donor (product)-specific anti-HLA antibodies (DSA) at screening
(Note: Only applicable for Phase 2)

For subjects with CLL/SLL:

- Diagnosis of CLL/SLL

- Relapsed/refractory disease

- Subjects relapsed/refractory to BTKi therapy and high-risk disease

- Subjects relapsed/refractory with 2 or more lines of therapy including BTKi and BCL-2
inhibitor (venetoclax)

- At least 1 measurable lesion at time of enrollment

For all subjects:

- Male or female subjects ≥18 years of age

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

- Adequate hematological, renal, and liver function

Exclusion Criteria:

- Active central nervous system (CNS) involvement by malignancy

- Current thyroid disorder (including hyperthyroidism), except for subjects with
hypothyroidism controlled on a stable dose of hormone replacement therapy

- Any other active malignancies that required systemic treatment within 3 years prior to
enrollment

- Radiation therapy within 2 weeks prior to ALLO-647

- Prior irradiation to >25% of the bone marrow

- Hypocellular bone marrow for age by institutional standard as determined from a bone
marrow biopsy performed at time of screening (Note: Only applicable for Phase 2).

- Autologous hematopoietic stem cell transplant (HSCT) within last 6 months (24 weeks)

- Systemic anti-cancer therapy within 2 weeks prior to receiving ALLO-647

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/14/2024. Questions regarding updates should be directed to the study team contact.